Company Encyclopedia
View More
name
EASEPAL
002614.SZ
Xiamen Comfort Science&Technology Group Co., Ltd researches, develops, manufactures, and sells health massage appliances in China and internationally. The company offers massage chairs and appliances; fresh air systems and air purifiers;and other products. It offers its products under the OGAWA, FUJI, IHOCO, medisana, BRI, cozzia, joypal, EASEWELL, and MICODE brand names. The company was founded in 1996 and is based in Xiamen, China.
214.12 B
002614.SZMarket value -Rank by Market Cap -/-

Financial Score

15/12/2025 Update
B
Leisure ProductsIndustry
Industry Ranking8/35
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.55%C
    • Profit Margin1.34%C
    • Gross Margin33.68%C
  • Growth ScoreC
    • Revenue YoY8.69%B
    • Net Profit YoY15.91%B
    • Total Assets YoY4.71%C
    • Net Assets YoY-0.65%D
  • Cash ScoreB
    • Cash Flow Margin7477.82%A
    • OCF YoY8.69%B
  • Operating ScoreB
    • Turnover0.69B
  • Debt ScoreC
    • Gearing Ratio41.72%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "Artificial Intelligence + Healthcare" welcomes new policies, multiple listed companies are expected to benefit

    On November 4th, the National Health Commission issued the "Implementation Opinions on Promoting and Regulating the Development of 'Artificial Intelligence + Healthcare' Applications." Several A-share companies, such as SWS Medical, Yunnan Baiyao, and EASEPAL, have already laid out plans in the "Artificial Intelligence + Healthcare" field. The implementation opinions clarify the direction of industry support and key application areas, bringing new business expansion opportunities to related listed companies and aiding in performance growth

    Wallstreetcn·
    SZ
    000538
    +0.05%
    SZ
    002614
    +0.97%
    SH
    688410
    +0.27%
    Wallstreetcn·
    SZ
    000538
    +0.05%
    SZ
    002614
    +0.97%
    SH
    688410
    +0.27%

    EASEPAL: Net profit in the third quarter was 28.2427 million yuan, a year-on-year increase of 3.47%

    EASEPAL announced that its revenue for the third quarter was 1.397 billion yuan, a year-on-year increase of 13.40%; net profit was 28.2427 million yuan, a year-on-year increase of 3.47%. Revenue for the first three quarters was 3.724 billion yuan, a year-on-year increase of 8.43%; net profit was 55.2741 million yuan, a year-on-year increase of 8.37%

    Zhitong·
    SZ
    002614
    +0.97%
    Zhitong·
    SZ
    002614
    +0.97%

    EASEPAL: Net profit of 27.0314 million yuan in the first half of 2025, a year-on-year increase of 14.01%

    EASEPAL announced that in the first half of 2025, operating revenue reached 2.327 billion yuan, a year-on-year increase of 5.65%. Net profit was 27.0314 million yuan, a year-on-year increase of 14.01%

    Zhitong·
    SZ
    002614
    +0.97%
    Zhitong·
    SZ
    002614
    +0.97%

    EASEPAL: The company has resumed shipping original orders to American customers

    On June 30th, EASEPAL stated on the interactive platform that the company has resumed shipping original orders to American customers

    Zhitong·
    SZ
    002614
    +0.97%
    Zhitong·
    SZ
    002614
    +0.97%

    EASEPAL: The company did not participate in the investment in New Kailai

    On April 11th, EASEPAL stated on the interactive platform that the company did not participate in the investment in New Kylin

    Zhitong·
    SZ
    002614
    +0.97%
    Zhitong·
    SZ
    002614
    +0.97%
    © 2025 Longbridge｜Disclaimer